Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4

NCT00003280 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00003280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
January 31, 1998
Completion date
March 31, 2002
Enrollment
240 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma